Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Reg FD disclosure furnished under Item 7.01 and excluded from Exchange Act Section 18 filing liability.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure furnished under Item 7.01 and excluded from Exchange Act Section 18 filing liability
- Disclosure not incorporated by reference into Securities Act or Exchange Act filings absent explicit reference
Item 8.01 · Other Events
- LOTIS-5 met its PFS endpoint: median 6.1 months vs 4.7 months, HR 0.73, p=0.008
- ZYNLONTA combination improved ORR 58.1% vs 45.2% and CR rate 39.5% vs 26.7%
- Durability favored ZYNLONTA: median DOR 9.2 vs 7.7 months and DoCR 16.8 vs 12.3 months
- Safety tradeoff: Grade 5 TEAEs 13.2% vs 4.6%, serious adverse events 49.0% vs 34.5%, withdrawals 25.5% vs 9.1%
- FDA pre-sBLA meeting planned for August, with sBLA submission targeted for fourth quarter 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.